Miller Fisher syndrome following COVID-19 vaccines: A scoping review

Jee-Eun Kim1, Byeol-A Yoon2,3, Yoo Hwan Kim4

  • 1Department of Neurology, Ewha Womans University College of Medicine, Seoul, Korea.

Abstract

Insights

Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), is a rare adverse event following COVID-19 vaccination. This study identified MFS cases, noting distinct characteristics compared to MFS post-infection and GBS post-vaccination.

Area of Science:

  • Neurology
  • Immunology
  • Vaccinology

Background:

  • Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barré Syndrome (GBS).
  • Adverse events (AEs) following COVID-19 vaccination require thorough evaluation.
  • MFS post-COVID-19 vaccination may be underestimated.

Purpose of the Study:

  • To identify and characterize cases of MFS following COVID-19 vaccination.
  • To compare MFS post-vaccination with MFS post-infection and GBS post-vaccination.

Main Methods:

  • Systematic literature search of MEDLINE, Embase, and other databases.
  • Inclusion of studies reporting MFS cases during the COVID-19 pandemic.

Main Results:

  • Nine cases of MFS following COVID-19 vaccination were identified.
  • Anti-GQ1b antibody positivity was frequent in MFS post-vaccination (44%).
  • MFS post-vaccination was less commonly associated with viral-vector vaccines (22%) compared to GBS.

Conclusions:

  • MFS following COVID-19 vaccination exhibits a different pathophysiology than MFS post-infection and GBS post-vaccination.
  • MFS should be considered a potential AE of COVID-19 vaccination due to its rare incidence and diagnostic challenges.